Quick Answer
A PMA submission is a premarket approval application to FDA for a Class III medical device. PMA is FDA's most stringent device marketing application and requires valid scientific evidence showing reasonable assurance of safety and effectiveness for the device's intended use. A PMA package typically includes device description, indications, nonclinical and clinical evidence, manufacturing information, labeling, financial disclosures, pediatric information when available, and other information required under 21 CFR Part 814.
Key Takeaways
- PMA is generally required for Class III devices when general and special controls are not sufficient to assure safety and effectiveness.
- FDA must approve the PMA before the device can be marketed in the United States.
- PMA is different from 510(k): 510(k) clearance is based on substantial equivalence, while PMA approval is based on independent evidence of safety and effectiveness.
- FDA's PMA review includes administrative and filing review, substantive scientific and regulatory review, possible advisory committee review, and final FDA action.
- Some PMA application and supplement types can use eSTAR voluntarily, but PMA is not broadly subject to the same mandatory eSTAR rule as 510(k) and De Novo.
- A PMA submission is the highest-burden FDA device pathway. It is used when the device is high risk, supports or sustains human life, is important in preventing impairment of human health, or presents a potential unreasonable risk of illness or injury.
- The practical issue is that PMA is not only a larger version of a 510(k). It is a different regulatory case. FDA is not asking whether the device is substantially equivalent to a predicate. FDA is asking whether the application contains sufficient valid scientific evidence to support reasonable assurance of safety and effectiveness for the proposed intended use.
- This guide explains when PMA applies, what FDA expects in a PMA application, how review works, and where submission teams most often lose time.
- In this guide, you will learn:
- What a PMA submission is
- When PMA applies instead of 510(k) or De Novo
- What content belongs in a PMA application
- How FDA PMA review works
- How Assyro supports PMA submission readiness
- Related guides:
- From QMSR to eSTAR
- Quality records for regulatory submissions
- 510(k) submission guide
- De Novo submission guide
- 510(k) vs De Novo classification
- Medical device regulatory submission software
What Is a PMA Submission?
A PMA submission, or premarket approval application, is an FDA marketing application for certain Class III medical devices. FDA reviews the application to determine whether valid scientific evidence provides reasonable assurance that the device is safe and effective for its intended use.
FDA describes PMA as the most stringent type of device marketing application. A PMA-approved device may not be marketed until FDA issues an approval order.
PMA usually applies when:
- The device is Class III
- The device supports or sustains human life
- The device is of substantial importance in preventing impairment of human health
- The device presents a potential unreasonable risk of illness or injury
- General controls and special controls are not sufficient to assure safety and effectiveness
- A 510(k) or De Novo pathway is not appropriate
PMA is common for high-risk devices such as certain implantable devices, life-sustaining devices, and some diagnostic or therapeutic technologies where clinical evidence is central to the safety and effectiveness determination.
PMA vs 510(k) vs De Novo
| Pathway | FDA Decision Basis | Typical Use Case |
|---|---|---|
| 510(k) | Substantial equivalence to a legally marketed predicate | Moderate-risk device with a valid predicate |
| De Novo | Risk-based Class I or II classification for a novel device | Novel low-to-moderate-risk device with no predicate |
| PMA | Valid scientific evidence of safety and effectiveness | High-risk Class III device |
If a device can be cleared through 510(k), PMA is usually not the right pathway. If a device is novel but low-to-moderate risk, De Novo may be appropriate. If risk is high or evidence must independently establish safety and effectiveness, PMA is the likely route.
PMA Submission Requirements Under 21 CFR Part 814
PMA content requirements are described in 21 CFR 814.20 and related FDA guidance. FDA's PMA application contents page explains that there is no preprinted PMA form, but the application must include required elements unless an omission is justified.
Core PMA content includes:
| PMA Area | What FDA Expects |
|---|---|
| Applicant information | Applicant name, address, authorized representative where applicable, and signature |
| Table of contents | A detailed structure identifying volumes, sections, and page references |
| Summary | Enough information for a reader to understand indications, device description, alternatives, marketing history, data summary, and conclusions |
| Device description | How the device functions, scientific concepts, physical and performance characteristics, components, accessories, and materials |
| Indications for use | Disease or condition, intended patient population, users, setting, and clinical purpose |
| Alternative practices | Existing diagnostic, treatment, prevention, or mitigation options |
| Nonclinical studies | Bench, animal, laboratory, engineering, biocompatibility, electrical safety, software, cybersecurity, sterilization, shelf-life, or other testing as applicable |
| Clinical investigations | Human subject evidence supporting safety and effectiveness when needed |
| Manufacturing information | Methods, facilities, controls, quality information, and process information sufficient for FDA review |
| Labeling | Proposed labeling, instructions, warnings, contraindications, limitations, and promotional claims support |
| Financial disclosure | Certification or disclosure information required under 21 CFR Part 54 |
| Pediatric information | Readily available pediatric subpopulation information required by regulation |
| Other information | Any additional information FDA requests or device-specific guidance requires |
The PMA must be internally consistent. A common readiness failure is that the clinical evidence supports one claim, the labeling implies another, and the manufacturing or risk documentation does not fully support commercial use.
Valid Scientific Evidence
PMA depends on valid scientific evidence. For many PMA devices, that includes clinical data, but the exact evidence package depends on the device type, risk, indications, technology, and FDA feedback.
The submission should explain:
- Why the selected study design supports the intended use
- How endpoints connect to clinically meaningful safety and effectiveness
- How adverse events, device failures, and risk controls were evaluated
- How nonclinical testing supports device performance
- How manufacturing controls support the device that will be marketed
- How labeling reflects actual evidence and residual risk
PMA Submission Methods
FDA describes several PMA application methods.
| Method | Use Case | Practical Implication |
|---|---|---|
| Traditional PMA | Complete PMA application submitted at once | Best when evidence and manufacturing information are mature |
| Modular PMA | PMA content submitted in defined modules over time | Useful for some devices when FDA and the applicant agree on modular review |
| Product Development Protocol | FDA and sponsor agree prospectively on development and testing | Less common, but can align evidence generation early |
| Humanitarian Device Exemption | Device intended to benefit patients with rare diseases or conditions | Different statutory standard and use case than traditional PMA |
Most teams thinking about "PMA submission" are referring to a traditional PMA. Modular PMA can be useful when the development program is complex and FDA interaction is needed before the complete application is ready.
PMA Review Process
FDA describes PMA review as a four-step process:
- Administrative and limited scientific review to determine completeness
- In-depth scientific, regulatory, and Quality System review
- Advisory committee review and recommendation when applicable
- Final FDA deliberation, documentation, and action
Acceptance and Filing Review
After FDA receives a PMA, the agency performs administrative and filing review. FDA determines whether the application is suitable for filing based on the statute, PMA regulations, and the PMA acceptance and filing review policy.
Filing risk often comes from missing administrative content, incomplete sections, unclear device descriptions, absent study reports, or failure to provide information FDA needs to begin substantive review.
Substantive Review
During substantive review, FDA evaluates safety, effectiveness, manufacturing, labeling, biostatistics, clinical evidence, nonclinical evidence, and quality system information. FDA may issue major deficiency letters when the application cannot support approval in its current form.
Common PMA review risks include:
- Clinical evidence does not support the proposed indication
- Primary endpoints or statistical analyses are not persuasive
- Safety signals are not adequately explained
- Manufacturing information does not support commercial production
- Labeling claims exceed the evidence
- Human factors, software, cybersecurity, sterilization, biocompatibility, or electrical safety evidence is incomplete
- Cross-references and version control fail under review pressure
FDA Action
FDA may approve the PMA, issue an approvable letter with conditions, issue a not approvable letter, or take another action depending on the review status and evidence. PMA approval may include postapproval requirements, conditions of approval, periodic reporting, or requirements for supplements before certain changes.
PMA Supplements and Lifecycle Changes
PMA work continues after approval. FDA states that a PMA supplement is generally required before making a change affecting the safety or effectiveness of an approved PMA device, unless another permitted submission type applies.
PMA supplement categories can include:
- Panel-track supplements for significant changes that may need substantial clinical data
- 180-day supplements for changes affecting safety or effectiveness
- Real-time supplements for narrower changes suitable for interactive review
- Special PMA supplements for certain changes being effected
- 30-day notices for certain manufacturing or process changes
This means PMA teams need a lifecycle strategy, not only an original application strategy. The submission system should preserve evidence, decisions, labeling rationale, and postapproval change history.
eSTAR and PMA Submissions
FDA requires eSTAR for 510(k) submissions as of October 1, 2023 and De Novo submissions as of October 1, 2025, unless exempted. PMA is different.
FDA's eSTAR page states that IDEs, Pre-Submissions, and certain PMA application and supplement types can be voluntarily submitted as eSTARs through the CDRH Portal or mailed to FDA. FDA also states that CBER is voluntarily accepting eSTAR for medical device PMAs, IDEs, and Pre-Submissions.
The key point: PMA teams should not assume eSTAR is mandatory for all PMA filings. They should confirm the current FDA eSTAR page, center, application type, and review division expectations before choosing the submission format.
How Assyro Supports PMA Submission Readiness
PMA readiness depends on more than assembling a large package. The application must align device description, clinical evidence, nonclinical testing, manufacturing controls, labeling, and risk management into one coherent regulatory argument.
Assyro supports medical device submission teams through medical device regulatory submission software, eSTAR Validation, and readiness workflows that help identify missing content, inconsistent cross-references, and weak evidence-to-claim logic before FDA review.
For PMA teams, the high-value workflow is evidence coherence: confirm that the intended use, risk profile, clinical data, manufacturing information, and labeling all support the same safety and effectiveness case.
A PMA submission is a premarket approval application to FDA for certain Class III medical devices. It asks FDA to approve the device based on valid scientific evidence showing reasonable assurance of safety and effectiveness.
References
This guide reflects FDA PMA and eSTAR information current as of May 2026. Confirm current FDA guidance, device-specific guidance, classification information, and review division feedback before filing.
About the author
Assyro Team
Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.
See Assyro in action
Catch eCTD and eSTAR errors before your FDA review cycle.
Book a 20-minute demo this week. We'll validate a sample of your submission live and show you exactly where Assyro catches what your current QC misses.